Cargando...

Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Chemotherapy has historically proven toxic and ineffective for the treatment of metastatic hormone-refractory prostate cancer (HRPC), a disease with substantial morbidity and mortality. Progress has been made in symptom relief, and the combination of mitoxantrone and prednisone is considered the pal...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Petrylak, Daniel P
Formato: Artigo
Lenguaje:Inglês
Publicado: MedReviews, LLC 2003
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1502327/
https://ncbi.nlm.nih.gov/pubmed/16986041
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!